Showing results (231-240 of 406) with videos related to
Sort By:
Pageof 41
Blood|April 28, 2010
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemiaFelicitas Thol, Frederik Damm, Katharina Wagner, et al.Frontiers in Immunology|July 5, 2022
Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage DisplaySteffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, et al.Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.Haematologica|September 25, 2025
Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approachesMaximilian Al-Bazaz, Sven Pischke, Winfried Alsdorf, et al.Leukemia & Lymphoma|June 2, 2020
Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effectsLina Jansen, Maximilian Merz, Monika Engelhardt, et al.Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.Oncoimmunology|July 29, 2016
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapySusanne M Rittig, Maik Haentschel, Katrin J Weimer, et al.Blood|September 30, 2006
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approachStefan Balabanov, Artur Gontarewicz, Patrick Ziegler, et al.Blood|December 11, 2012
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signalingStefanie Bugl, Stefan Wirths, Markus P Radsak, et al.Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.Pageof 41